Cellectar biosciences expands global intellectual property portfolio with four patent grants

Florham park, n.j., oct. 02, 2023 (globe newswire) -- cellectar biosciences, inc. (nasdaq: clrb), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced significant advancements to its global intellectual property (ip) portfolio.
CLRB Ratings Summary
CLRB Quant Ranking